Page last updated: 2024-09-03

clofarabine and Uterine Neoplasms

clofarabine has been researched along with Uterine Neoplasms in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
DiFeo, A; Haanen, TJ; Hurst, L; Miller, KM; Mohan, A; Narla, G; Noto, FK; O'Connor, CM; Sangodkar, J; Suhan, TK; Taylor, SE; Trako, J; Zamarin, D; Zawacki, KP	1

Other Studies

1 other study(ies) available for clofarabine and Uterine Neoplasms

Article	Year
Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma. Cancer research, 2022, 02-15, Volume: 82, Issue:4 Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Clofarabine; Cystadenocarcinoma, Serous; Female; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Protein Phosphatase 2; Rats, Sprague-Dawley; Ribonucleotide Reductases; Synthetic Lethal Mutations; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays	2022

Article

Year

Targeting Ribonucleotide Reductase Induces Synthetic Lethality in PP2A-Deficient Uterine Serous Carcinoma.

Cancer research, 2022, 02-15, Volume: 82, Issue:4

Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Survival; Clofarabine; Cystadenocarcinoma, Serous; Female; Humans; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Protein Phosphatase 2; Rats, Sprague-Dawley; Ribonucleotide Reductases; Synthetic Lethal Mutations; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays

2022